Fibrosis is a common pathway in many diseases affecting organs such as the liver, kidney and heart. When cardiac tissue is injured, fibrogenesis is initiated as part of the repair process and the development of fibrosis and its consequences can lead to eventual heart failure. There is a need for non-invasive and sensitive biomarkers that can detect early changes in fibrosis development.
ATH001 is a radiopharmaceutical that is being developed to probe the presence of platelet-derived growth factor receptor beta (PDGFRβ) using Positron Emission Tomography (PET). PDGFRβ is a marker of ongoing fibrogenesis in tissue. ATH001 enables tissue-specific quantification of active fibrotic disease. You can read more about ATH001 data that was presented at EANM’25 and about imaging fibrogenesis and fibrosis.
Uppsala University has recently published data on ATH001 in myocardial infarction which complements a growing body of evidence in liver fibrogenesis, demonstrating the promise of ATH001 as a probe for PDGFRβ and a non-invasive tool for imaging fibrogenesis. Be enabling early and precise visualisation and quantification of active fibrogenesis in the heart, ATH001 provides a powerful biomarker that can accelerate cardiac drug development, optimise patient selection, and support mechanism of action for emerging antifibrotic therapies.
Publication details:
Title: GA-68-Labeled Affibody Molecule-Based Radiopharmaceutical Targeting Platelet Derived Growth Factor Receptor Beta for Detection of Active Fibrosis in Patients with Myocardial Infarction
Authors: Velikyan I, Grinnemo KH, Flodin V, James S, Thelander U, Wagner M, Rodin S, Kero T, Korsgren O. Eriksson O
Find the publication link here
About Antaros Tracer
Antaros Tracer is a sister company to Antaros Medical, formed to ensure an expedited and focused development of new Positron Emission Tomography (PET) tracers to be used as important biomarkers in drug development studies. Current disease area focus is fibrotic disease and immune-system activation in immune-oncology, inflammatory disease, and immunology.
About Antaros Medical
Antaros Medical is in the forefront of imaging solutions for drug development, combining imaging expertise with extensive knowledge in drug development and disease biology to design and deliver clinical trials for decision-making and differentiation. With global collaborations with pharmaceutical companies across metabolic, fibrotic and inflammatory diseases, Antaros Medical is providing key answers in every stage of drug development, from early to late-stage clinical trials. Antaros Medical’s headquarter and CoreLab is based in Sweden, with a subsidiary in the US.